CN103040735A - Spirulina polysaccharide eye drop - Google Patents
Spirulina polysaccharide eye drop Download PDFInfo
- Publication number
- CN103040735A CN103040735A CN2012105945450A CN201210594545A CN103040735A CN 103040735 A CN103040735 A CN 103040735A CN 2012105945450 A CN2012105945450 A CN 2012105945450A CN 201210594545 A CN201210594545 A CN 201210594545A CN 103040735 A CN103040735 A CN 103040735A
- Authority
- CN
- China
- Prior art keywords
- eye drop
- eye
- spirulina polysaccharide
- centrifugal
- spirulina
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to a spirulina polysaccharide eye drop, in particular to an eye buffer solution containing spirulina polysaccharide with effective active concentration. According to the invention, the spirulina polysaccharide is prepared into an eye drop for the first time and applied to prevention and treatment of bacterial keratitis. The eye drop disclosed by the invention has a simple and easy-to-implement preparation method, can obtain a remarkable effect in prevention and treatment of the bacterial keratitis, and has a wide application and development prospect.
Description
Technical field
The invention belongs to the eye drop technical field, be specifically related to a kind of spirulina polysaccharide eye drop, be i.e. the eye drop of a kind of prevention and treatment bacterial keratitis.
Background technology
Antibacterial be keratitis most commonly encountered diseases because of, bacterial keratitis is one of main diseases causing blindness, malpractice can cause permanent visual deterioration, even blind.The most effective approach for the treatment of for keratitis is exactly the topical application antibiotic at present.But antibiotic produces drug resistance easily, therefore, seek the bioactive substance that has safely and effectively antibacterial activity and be very important for prevention and treatment eye bacterial keratitis relevant disease, begin in recent years to be subject to various countries scholar's attention, but still do not have relevant application report.
Summary of the invention
The purpose of this invention is to provide a kind of spirulina polysaccharide eye drop, to remedy the shortage of existing bacterial keratitis treatment and prophylactic agent.
Eye drop of the present invention is the eye buffer of the spirulina polysaccharide that comprises effective active concentration.
Spirulina polysaccharide concentration wherein is preferably 100 μ g/ml;
Described buffer is that eye is with commonly using solution system, for example artificial tears or sodium chloride eye drop in the eye drop.
The used spirulina polysaccharide of the present invention is take spirulina plalensis (Spirulina platensis) algae powder as raw material, and extraction prepares and gets.
Spirulina polysaccharide eye drop of the present invention is applied to the treatment of eye keratitis disease.
The present invention makes spirulina polysaccharide first eye drop and is applied to control eye bacterial keratitis disease.Eye drop preparation method of the present invention is simple, is convenient to implement, and is remarkable for the prevention effect of ocular neovascular, has wide application and development prospect.
The specific embodiment
Spirulina is the most ancient original Sargassum of many cells.Spirulina has the effects such as significant blood sugar lowering, blood pressure lowering, blood fat reducing according to reports.Only accounting for the spirulina polysaccharide of 2-3% in the spirulina chemical constituent, have extensive and complicated biological activity, have medicinal curative effect at antitumor and radioprotective, is a kind of safely and effectively bioactive substance.But spirulina only is used in the middle of health product and the food at present, and the applicant studies for a long period of time and finds the not only effectively growth of anti-bacteria of spirulina polysaccharide, can also control the generation of ocular angiogenesis, thereby facilitate the present invention.
The spirulina polysaccharide (Spriulina polysacchrides) that the present invention is used is called again polysaccharides, and is from the physiologically active polysaccharide that spirulina extracts, nontoxic; Be colourless or pale yellow powder.Water-soluble, be insoluble to pure and mild oils and fats.The spirulina polysaccharide commercial prod that the used eye drop of the present invention can select arbitrary money medicine food field to use.
The present invention is dissolved in eye with the preparation of finishing product in the buffer with spirulina polysaccharide, and wherein eye can be the artificial tears with a buffer, and the artificial tears imitates a kind of succedaneum that the composition of human body tear is made.It is a kind of collyrium, can play the effect of moistening eyes.The present invention can select the artificial tears of arbitrary money.
As a concrete enforcement, the used spirulina polysaccharide of the present invention is take spirulina plalensis algae powder (production of Shandong Fu Shite Bioisystech Co., Ltd) as raw material, extraction has prepared spirulina polysaccharide, then be diluted to a kind of eye take bioactive substance as main component with the artificial tears and use eye drop, be used for the treatment of bacterial keratitis.Spirulina polysaccharide concentration wherein can be selected according to patient's situation, is preferably 100 μ g/ml.
Concrete preparation method is as follows:
The preparation of step 1, spirulina polysaccharide: prepare spirulina polysaccharide required for the present invention with following technique.
(1) gets spirulina plalensis dry powder and add 95% ethanol, soaked overnight;
(2) centrifugal 37 ℃ of oven dry, the 1:12 ratio adds distilled water in mass ratio;
(3) transfer pH to 10.0,80 ℃ of water-bath 4 ~ 6h with NaOH;
(4) centrifugal, adding mass volume ratio in will precipitating is 5% trichloroacetic acid precipitation, and 4 ℃ are spent the night;
(5) centrifugal, get supernatant, adding mass volume ratio is 5% trichloroacetic acid precipitation 3h again;
(6) centrifugal, get supernatant, add 5 times of volume ethanol precipitations, 4 ℃ are spent the night;
(7) with pure acetone washing and precipitating 2 times, vacuum lyophilization;
(8) above-mentioned precipitate is placed-20 ℃ preserve more than 3 days, volatilize fully to guarantee acetone;
(9) add the abundant dissolution precipitation of normal saline, centrifugal, remove the material of failing to dissolve;
(10) use 0.22 μ m membrane filtration degerming, obtained aseptic spirulina polysaccharide solution.
Step 2, use the artificial tears to be diluted to spirulina polysaccharide content 100 μ g/ml above-mentioned spirulina polysaccharide solution, namely obtain spirulina polysaccharide eye drop of the present invention.The used artificial tears of the present invention is that the artificial tears of not adding preservative agent is such as 0.1% hyaluronate sodium and hydroxypropyl emthylcellulose.
Above-mentioned artificial tears can substitute with the sodium chloride eye drop (if as replacing compound sodium chloride eye drop solution).
The effect that regards to down the eye drop of the present invention's preparation is described:
Model rabbit bacterial keratitis animal model: animal pattern is selected the 2.5-3kg new zealand white rabbit, the rabbit general anesthesia, and proxymetacaine hydrochloride eye drop eye dripping, carrying out substrate with the substrate injection needle in cornea central authorities, to inject 5 μ l concentration be 2 * 10
4The bacterium liquid of CFU/ml (i.e. 100 bacterium) causes the rabbit corneal bacterial keratitis to infect.
Rabbit bacterial keratitis animal model to above-mentioned foundation is divided into 3 groups, every group of 12 animals, and after 8 hours, the starting point ocular administration gives respectively the present invention spirulina polysaccharide eye drop, levofloxacin and the normal saline of preparation in corneal stroma injection bacterium liquid.The eye drip scheme is as follows: 15min/ time before this, eye drip is 5 times continuously, and then 30min/ time, eye drip is 14 times continuously, and the 1h observation rabbit experimental eye after last eye drip end is also given by following standards of grading and divided statistical analysis.
The pathological changes standards of grading see the following form:
The slit lamp standards of grading
Put to death immediately rabbit after observing end, randomly draw 9 pathological changes rabbit corneas and use the 8.5mm corneal trephines to drill through cornea from cornea central authorities, remain and do the pathology analysis after 3 pathological changes lagophthalmos are won eyeball.The cornea that drills through uses the homogenate of sterilization buffer, presses 1:10 gradient dilution to 10
-5, to choose three suitable dilution bacterium liquid sucking-off 0.1ml and coat nutrient agar panel, 37 degree are cultivated 24h, the row colony counting.
The result shows, after adopting substrate injection staphylococcus aureus to induce the rabbit bacterial keratitis, then carry out levofloxacin or spirulina polysaccharide eye drop of the present invention and carry out frequent eye dripping treatment, slit lamp observation scoring score value shows, normal saline matched group 13 minutes, levofloxacin eye dripping group 7 minutes, and spirulina polysaccharide eye drop eye dripping group is 6 minutes, slit lamp observation finds that spirulina polysaccharide eye drop shows with respect to the eye that levofloxacin can more effectively improve disease eye, and conjunctival sac secretions and conjunctiva, cornea, anterior chamber's inflammatory reaction etc. all has significantly and alleviates.
Claims (5)
1. an eye drop is characterized in that, described eye drop is the eye buffer that comprises the spirulina polysaccharide of effective active concentration.
2. eye drop as claimed in claim 1 is characterized in that the concentration of described spirulina polysaccharide in eye drop is 100 μ g/ml.
3. eye drop as claimed in claim 1 or 2 is characterized in that, the preparation of described spirulina polysaccharide comprises the steps:
(1) gets spirulina plalensis dry powder and add 95% ethanol, soaked overnight;
(2) centrifugal 37 ℃ of oven dry, the 1:12 ratio adds distilled water in mass ratio;
(3) transfer pH to 10.0,80 ℃ of water-bath 4 ~ 6h with NaOH;
(4) centrifugal, adding mass volume ratio in will precipitating is 5% trichloroacetic acid precipitation, and 4 ℃ are spent the night;
(5) centrifugal, get supernatant, adding mass volume ratio is 5% trichloroacetic acid precipitation 3h again;
(6) centrifugal, get supernatant, add 5 times of volume ethanol precipitations, 4 ℃ are spent the night;
(7) with pure acetone washing and precipitating 2 times, vacuum lyophilization;
(8) above-mentioned precipitate is placed-20 ℃ preserve more than 3 days, volatilize fully to guarantee acetone;
(9) add the abundant dissolution precipitation of normal saline, centrifugal, remove the material of failing to dissolve;
(10) use 0.22 μ m membrane filtration degerming, obtained aseptic spirulina polysaccharide solution.
4. eye drop as claimed in claim 1 is characterized in that described eye is artificial tears or sodium chloride eye drop with buffer.
5. eye drop claimed in claim 1 is applied to the treatment of eye keratitis disease.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012105945450A CN103040735A (en) | 2012-12-31 | 2012-12-31 | Spirulina polysaccharide eye drop |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012105945450A CN103040735A (en) | 2012-12-31 | 2012-12-31 | Spirulina polysaccharide eye drop |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103040735A true CN103040735A (en) | 2013-04-17 |
Family
ID=48053748
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2012105945450A Pending CN103040735A (en) | 2012-12-31 | 2012-12-31 | Spirulina polysaccharide eye drop |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103040735A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108379242A (en) * | 2018-05-06 | 2018-08-10 | 广州加原医药科技有限公司 | A kind of allicin spirulina polysaccharide polvmeric lipid nano particle preparations and preparation method |
| CN108553453A (en) * | 2018-06-06 | 2018-09-21 | 广西大学 | Spirulina extract anti-inflammatory effect studies the structure and application method of animal model |
| IT202000013156A1 (en) | 2020-06-03 | 2021-12-03 | Welifepharma Sagl | LIQUID OPHTHALMIC COMPOSITION INCLUDING AN AQUEOUS EXTRACT OF SPIRULINA PLATENSIS. |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101444480A (en) * | 2008-12-26 | 2009-06-03 | 山东省眼科研究所 | Spirulina polysaccharide eye drop, and preparation method and application thereof |
-
2012
- 2012-12-31 CN CN2012105945450A patent/CN103040735A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101444480A (en) * | 2008-12-26 | 2009-06-03 | 山东省眼科研究所 | Spirulina polysaccharide eye drop, and preparation method and application thereof |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108379242A (en) * | 2018-05-06 | 2018-08-10 | 广州加原医药科技有限公司 | A kind of allicin spirulina polysaccharide polvmeric lipid nano particle preparations and preparation method |
| CN108553453A (en) * | 2018-06-06 | 2018-09-21 | 广西大学 | Spirulina extract anti-inflammatory effect studies the structure and application method of animal model |
| IT202000013156A1 (en) | 2020-06-03 | 2021-12-03 | Welifepharma Sagl | LIQUID OPHTHALMIC COMPOSITION INCLUDING AN AQUEOUS EXTRACT OF SPIRULINA PLATENSIS. |
| WO2021245179A1 (en) | 2020-06-03 | 2021-12-09 | Welifepharma Sagl | Liquid ophthalmic composition comprising a spirulina platensis full extract |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102145126B (en) | Pharmaceutical composition for treating xerophthalmia | |
| TWI558405B (en) | Cicada active material, a preparation method thereof, a pharmaceutical composition comprising the same and a use thereof | |
| CN101648018A (en) | Medicinal composition for treating ophthalmic inflammation and application thereof | |
| CN101766628A (en) | Ophthalmic bacterial-infection resisting medicine for external use | |
| CN109045063A (en) | A kind of injecting temperature sensitive in situ response water soluble chitosan composite hydrogel and its preparation method and application for lacrimal passage embolism | |
| CN106236706A (en) | A kind of levofloxacin hydrochloride slow release eye drop | |
| CN106265768A (en) | Periostracum cicadae active substance, its preparation method, the medical composition comprising it and application thereof | |
| CN103040735A (en) | Spirulina polysaccharide eye drop | |
| CN105106318B (en) | A kind of Chinese medicine composition and preparation method thereof for treating xerophthalmia | |
| CN108125996A (en) | It is a kind of for visual fatigue, dry eyes eye-drops preparations | |
| CN114869885A (en) | Preparation of honokiol ophthalmic medicine and application of honokiol ophthalmic medicine in fungal keratitis treatment | |
| CN108042626A (en) | It is a kind of have to remove earwax and the composition of bacteriostasis efficacy, preparation and its application | |
| Yarmamedov et al. | Study of the pharmacological impact of polymeric membranes with antibacterial effect in traumatic lesions of cornea | |
| CN102188695B (en) | Ophthalmic gel composition | |
| CN102688479B (en) | Composition for preventing xerophthalmia, eye mask with composition and preparation method of eye mask | |
| CN109865016A (en) | A kind of pharmaceutical composition and its preparation method and application for treating xerophthalmia | |
| CN105327342A (en) | Ointment for treating skin eczema and insect bite dermatitis and preparation method of ointment | |
| CN104367832A (en) | Compound dendrobe eye drops for treating xerophthalmia and preparation method thereof | |
| CN101480439A (en) | Compound Chinese lobelia oral preparation and preparation method thereof | |
| CN106265720A (en) | A kind of combined artificial tear and preparation method thereof | |
| CN112891326B (en) | Natamycin-loaded alginic acid gel medicine film and preparation method thereof | |
| CN101444480A (en) | Spirulina polysaccharide eye drop, and preparation method and application thereof | |
| CN108066278B (en) | Gynecological gel containing chitosan oligosaccharide and preparation method thereof | |
| CN105963319A (en) | Saturated hydrogen saline water washing liquor and preparation method and application thereof | |
| CN111001010A (en) | External eye operation flushing fluid and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20130417 |